Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 48Unknown 15Terminated 10Active not recruiting 6Recruiting 5Withdrawn 4Suspended 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 7Biopsy 6Nivolumab 4Capecitabine 4Bevacizumab 4Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Cyclophosphamide 3Cisplatin 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2decitabine and cedazuridine drug combination 2daratumumab 2Vincristine 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Etoposide 2Epirubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Afatinib × Clear all
NCT02470065 2016-01-22

REMNANT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Suspended
38 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡